Yarlagadda Babu - BioCryst Pharmaceuticals Insider

BioCryst Pharmaceuticals Inc -- USA Stock  

USD 5.2  0.12  2.36%

Sr. VP of Drug Discovery

Dr. Yarlagadda S. Babu, Ph.D., is Senior Vice President Drug Discovery of the company since October 2013. Dr. Babu was the Vice President Drug Discovery of Biocryst Pharmaceuticals Inc. He joined BioCryst in 1988 and was BioCrysts first fulltime employee
Age: 61  SVP Since 2013      
919 859-1314  www.biocryst.com
Babu has served as the Company?s Vice President ? Drug Discovery since 1992. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham.

Management Efficiency

The company has return on total asset (ROA) of (27.86) % which means that it has lost $27.86 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (251.64) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 54.16 M in liabilities with Debt to Equity (D/E) ratio of 224.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioCryst Pharmaceuticals Inc has Current Ratio of 1.54 which is within standard range for the sector.

Similar Executives

Found 1 records

SVP Since

Reed ClarkDimension Therapeutics Inc
2015

Entity Summary

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals Inc (BCRX) is traded on NASDAQ in USA. It is located in NORTH CAROLINA, U.S.A and employs 70 people. BioCryst Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Portfolio File Import Now
   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
Hide  View All  Next  Launch Portfolio File Import
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add BioCryst Pharmaceuticals Inc to your portfolio

Top Management

BioCryst Pharmaceuticals Leadership Team
Rob Bennett, President
Alane Barnes, VP
Yarlagadda Babu, SVP
Fred Cohen, Director, Ph.D
Stanley Erck, Director
George Abercrombie, Chairman
Robert Ingram, Director
Thomas Staab, President
Charles Sanders, Director
Jon Stonehouse, CEO
Lynne Powell, President
Sanj Patel, Director
Kenneth Lee, Director
William Sheridan, President, Ph.D
Nancy Hutson, Director

Stock Performance

BioCryst Pharmaceuticals Performance Indicators